Table 2 Univariate analysis of factors contributing to plasma bepridil concentration in patients with HF

Sex (Male/Female)

223/112

15/9

0.684^a

Age

70.33 ± 10.89^d

75.08 ± 10.51^d

0.019^c

Height (m)

1.63 ± 0.10^d

1.59 ± 0.11^d

0.058^c

Body weight (kg)

63.45 ± 13.81^d

58.21 ± 12.17^d

0.079^c

Body mass index (kg/m²)

23.63 ± 3.79^d

22.98 ± 3.87^d

0.570^c

Daily dose of bepridil (mg/kg body weight)

1.61 ± 0.59^d

2.18 ± 0.69^d

<0.001^c

Serum creatinine (mg/dL)

0.93 ± 0.41^d

1.12 ± 0.47^d

0.027^c

Ccr (mL/min)

69.68 ± 29.43^d

52.12 ± 28.43^d

0.002^c

LVEF (%)

63.51 ± 10.65^d

59.52 ± 10.23^d

0.029^c

Number of concomitant drugs

4.70 ± 3.51^d

8.17 ± 3.87^d

<0.001^c

  Carbamazepine, n (%)

1 (0.30)

0 (0)

1.000^b

  Clarithromycin, n (%)

1 (0.30)

0 (0)

1.000^b

  Aprindine, n (%)

7 (2.1)

3 (14.3)

0.023^b

  Verapamil

4 (1.2)

1 (4.3)

0.294^b

  Digoxin

4 (1.2)

0 (0.0)

1.000^b

  Amiodarone

3 (0.9)

0 (0.0)

1.000^b

  Diltiazem

6 (1.8)

0 (0.0)

1.000^b

  Nifedipine

5 (1.5)

0 (0.0)

1.000^b